Navigation Links
Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Date:4/26/2012

was developed by Shire to give patients more choice in how they take their phosphate binder. Submissions for national marketing authorisations of FOSRENOL in oral powder form have been made to Sweden and the other 27 European markets, with the first national approvals anticipated in Q2 2012.

Pipeline


REPLAGAL - for the treatment of Fabry disease

  • On March 14, 2012 Shire announced that it had withdrawn its Biologics License Application ("BLA") for REPLAGAL with the FDA. In 2009, and again in 2011, the FDA encouraged Shire to submit an application for the approval of REPLAGAL in the US. These discussions led Shire to file a BLA in November 2011 in anticipation of a quick review process and eventual approval. Recent interactions with the FDA in Q1 2012 led Shire to believe that the FDA would require additional controlled trials for approval. No concerns over the product's safety profile were raised by the FDA. Shire has concluded that the likely additional studies would cause a significant delay, and an approval of REPLAGAL for US patients would only be possible in the distant future. Shire therefore decided to withdraw its BLA. Patients currently treated with REPLAGAL in the US under treatment access programs will be transitioned off REPLAGAL therapy by June 30, 2012.

SPD476, MMX® mesalamine - for the treatment of diverticular disease

  • On March 30, 2012 Shire announced top-line results of the PREVENT2 trial, a Phase 3 investigational study of once-daily SPD476, MMX mesalamine in patients with a history of diverticulitis. The study did not meet the primary endpoint in reducing the rate of recurrence of diverticulitis over a two year treatment period. Shire will continue to analyze these data and those of the second study, PREVENT1, which was similar in design to PREVENT2 and will report later in the year. Although the
    '/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... July 7, 2015   Decision Resources Group ... in dialysis patient management in the U.S. versus ... by U.S. and EU5 nephrologists from approximately 1,870 ... are the most commonly used renal medications in ... differs considerably between the two regions.      ...
(Date:7/7/2015)... FRANCISCO , July 7, 2015 ... reach USD 1,197.7 million by 2020, growing at an estimated ... new study by Grand View Research, Inc. Introduction of innovative ... coupled with growing awareness levels pertaining to the advantages of ... the next six years. In addition, presence of untapped growth ...
(Date:7/7/2015)... , July 7, 2015 EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering of 32,000,000 units. Each unit ... Series A warrant to purchase one share of common ... Investors whose purchase of units in the offering would ...
Breaking Medicine Technology:Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3
... CHICAGO and ORANGE, Calif., Feb. 23, 2011 ... (SJHS), a $4.6 billion not-for-profit Catholic healthcare system based in ... in California, West Texas and Eastern New Mexico, has selected ... MDRX ) to streamline patient movement through their ...
... Caliper Life Sciences, Inc. (Nasdaq: ... announced a co-marketing agreement which will leverage Covaris, ... microfluidics technologies to develop automated workflows for next ... suite of solutions for library construction, sample analysis, ...
Cached Medicine Technology:St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 2St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 3St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 4St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 5Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 2Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 3
(Date:7/7/2015)... ... July 07, 2015 , ... Dermatologists from ... Ideas Festival (AIF), identifying 18 possible melanomas and 46 potential non-melanoma skin cancers ... additional testing. , The Aspen Ideas Festival, which was held from June 25 ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... the two firms have merged to form Camber Collective. Camber Collective provides ... The merger combines SwitchPoint’s strategy consulting expertise with Hope Consulting’s deep experience ...
(Date:7/7/2015)... Chicago, IL (PRWEB) , ... July 07, 2015 ... ... organized the only industry group whose board is limited to permit holders. The ... vision on how to move the industry forward and are committed to making ...
(Date:7/7/2015)... LINCOLN, R.I. (PRWEB) , ... July 07, 2015 , ... ... take the proper precautions, however, so Amica Insurance is sharing some safety tips. , ... activities, sports and gardening: , Leisure activities/sports, , Start slowly. ...
(Date:7/7/2015)... Michigan (PRWEB) , ... July 07, 2015 , ... ... the heart of Downtown Detroit was the site of the National Baptist Convention ... Wellness Initiative. Focusing on encouraging and promoting the collaboration of churches and their ...
Breaking Medicine News(10 mins):Health News:More than 700 Screened for Skin Cancer at 2015 Aspen Ideas Festival 2Health News:More than 700 Screened for Skin Cancer at 2015 Aspen Ideas Festival 3Health News:More than 700 Screened for Skin Cancer at 2015 Aspen Ideas Festival 4Health News:SwitchPoint and Hope Consulting Have Merged to Form Camber Collective 2Health News:Cannabis Growers and Dispensaries Form Medical Cannabis Alliance of Illinois 2Health News:Amica Insurance Has 7 Summer Safety Tips 2Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 2Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 3
... the trusted leader in clinical research management systems, announced ... the needs of customers. "Velos On-Demand," a software as ... out more broadly for the Velos eResearch product line. ... support individual studies and departments within research institutions, as ...
... ... ... 9, 2009 -- Broadlane announced today the signing of an exclusive agreement ... Broadlane Workforce Management® to help manage the $9 million annual workforce spend at their ...
... ... of the company,s skin care product line with the introduction of Eye Un-Puff. The existing ... Eyes and Nutri-Cover Eye Cream Concealer. The products work to reduce eye puffiness and conceal ... ...
... ... a Windows screen recorder that creates interactive movies for presentations, demonstrations and training. Version ... presentation in a smaller screen format. , ... Wollongong, NSW (PRWEB) July 9, 2009 -- NetPlay Software releases ...
... Calif., July 8 Beckman Coulter, Inc. (NYSE: BEC ... automate, and innovate complex biomedical testing, announces upcoming company presentations and ... http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ) , , , ... Release scheduled after market close on Thursday, July 30, 2009. , ...
... The Songs of Love ... creates uplifting, personalized songs for children and teens struggling with a ... is professionally produced with lyrics containing the child,s name and references ... pets. Songs are written and performed in the musical style that ...
Cached Medicine News:Health News:Velos, Inc. Launches 'Velos On-Demand' for Velos eResearch, Bringing Dynamically Scalable Economy to Customers 2Health News:Velos, Inc. Launches 'Velos On-Demand' for Velos eResearch, Bringing Dynamically Scalable Economy to Customers 3Health News:Scottsdale Healthcare Streamlines Contract Labor Process with Broadlane Workforce Management 2Health News:Scottsdale Healthcare Streamlines Contract Labor Process with Broadlane Workforce Management 3Health News:Scottsdale Healthcare Streamlines Contract Labor Process with Broadlane Workforce Management 4Health News:Janet Sartin Expands Line of Products That Reduce and Conceal Eye Puffiness and Fine Lines 2Health News:Janet Sartin Expands Line of Products That Reduce and Conceal Eye Puffiness and Fine Lines 3Health News:Instant Demo Screen Recorder Now With TrakMouse™ Technology 2Health News:Upcoming Beckman Coulter Investor Events Second Half of 2009 2Health News:Upcoming Beckman Coulter Investor Events Second Half of 2009 3Health News:Donate Your Car to the Songs of Love Car Donation Program 2
... Practice management software for ... a true multi-tasking, multi-office practice ... in database technology- Winx Pro ... will assist you in effectively ...
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The SE-9000 automated hematology analyzer provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test results for enhanced screening ability....
... offers three-dimensional VCS technology, ... and efficiency in white ... analysis. With its reputation ... HmX is an affordable ...
Medicine Products: